Every material Form 8-K Lantern Pharma Inc. has filed with the SEC since September 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lantern Pharma received a Nasdaq notice on September 25, 2026 saying it is out of compliance with the minimum market value of listed securities requirement of $35 million over the last 30 consecutive business days. The company has until March 24, 2027 to regain compliance, or it expects Nasdaq could begin delisting proceedings from the Nasdaq Capital Market.
Nasdaq notice dated September 25, 2026 cites Listing Rule 5550(b)(2) with a $35 million minimum market value requirement
Nasdaq also said the company does not meet Listing Rules 5550(b)(1) and 5550(b)(3)
Compliance period runs 180 calendar days, ending March 24, 2027
Regaining compliance requires a market value of at least $35 million for 10 consecutive business days
Lantern Pharma sold 3,669,725 shares or pre-funded warrants at $1.09 per share in a registered direct offering that closed on September 30, 2026, for approximately $4.0 million in gross proceeds before expenses. The company also issued unregistered warrants for up to 3,669,725 shares at $1.09 that could bring in about $4 million more if fully exercised, which would add to the number of shares outstanding and dilute existing shareholders.
Offering priced at $1.09 per share, with approximately $4.0 million in gross proceeds before expenses; closed September 30, 2026
Purchase warrants for up to 3,669,725 shares at $1.09 exercise price; exercisable only after stockholder approval, expiring five years after that approval
Company must seek stockholder approval within 90 days of September 28, 2026
Placement agent Rodman & Renshaw received a cash fee of 7% of gross proceeds, and the company plans to use net proceeds for working capital and general corporate purposes
On September 23, 2026, Lantern Pharma hosted a live webinar discussing its Open-Medicine AI multi-agentic platform for drug development. The filing is a Regulation FD disclosure that furnishes the presentation used in the webinar and provides a replay link, with no financial results or guidance included.
Webinar held September 23, 2026, covering the Open-Medicine AI multi-agentic platform for drug development
A webinar replay is available via a YouTube link and on the investors section of the company website
Presentation furnished as Exhibit 99.1 and incorporated by reference; the filing states it is not deemed filed under Section 18 of the Exchange Act
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lantern Pharma Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →